Enzon Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/25/2026)
| Balance Sheet | Total Assets | 42,813,000.00 | ROE | – |
| Balance Sheet | Total Equity | -2,525,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -3,010,000.00 | – | – |
| Cashflow | Operating Cash Flow | -3,010,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -7.00 | Div. Yield | – |
| Income | Net Income | -3,409,000.00 | P/E | – |
| Income | Shares Outstanding | 742,146.00 | P/B | – |
| Income | Total Revenue | 100.00 | P/S | – |
Ratios calculated on: –
Company Description
Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company´s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.enzon.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more